Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.20%
#2 aelf aelf +23.92%
#3 Bitway Bitway +21.89%
#4 Decred Decred +16.39%
#5 Starpower Starpower +11.64%
#6 Pons Pons +11.46%
#7 AtomOne AtomOne +10.65%
#8 TRIA TRIA +9.64%
#9 Wibx Wibx +8.12%
#10 Status Status +7.76%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Perseus Proteomics Inc. Perseus Proteomics Inc.

Perseus Proteomics Inc.

4882
Clasificación en acciones #30348
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology... Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Precio por acción
$0.93298493
Capitalización bursátil
$17.19M
Cambio (1 día)
-1.38%
Cambio (1 año)
-62.47%
País
JP
Comercio Perseus Proteomics Inc. (4882)

Categoría

Healthcare
Ganancias de Perseus Proteomics Inc. (4882)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Perseus Proteomics Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Perseus Proteomics Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
$33.59B -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
$25.20B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
$8.70B -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
$21.39B -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
$5.95B -
US